Results 1 to 10 of about 240,836 (199)

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England. [PDF]

Br J Clin Pharmacol
Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021.
Fisher L, Buka R, Byrne R, Black S, Curtis HJ, Wood C, Brown A, Bacon S, Croker R, Goldacre B, MacKenna B, Speed V.   +11 more
europepmc   +3 more sources

Andexanet Alfa in Emergency Cranial Neurosurgical Procedures: A Bicentric Analysis of Efficacy and Safety. [PDF]

Neurocrit Care
Background Factor Xa inhibitors are widely used anticoagulants but are associated with a known risk of bleeding complications. In 2018, andexanet alfa was approved as an antidote for the reversal of apixaban and rivaroxaban, demonstrating high efficacy ...
Hounchonou HF, Albrecht C, Jelinek J, Wild F, Polemikos M, Abu-Fares O, Negwer C, Meyer B, Al-Afif S, Krauss JK.   +9 more
europepmc   +2 more sources

Use of Andexanet Alfa to Reverse Heparin After Cardiopulmonary Bypass. [PDF]

Ann Thorac Surg Short Rep
Heparin is the primary anticoagulant used for cardiopulmonary bypass and requires reversal to prevent postoperative bleeding. Protamine sulfate is the only United States Food and Drug Administration–approved heparin reversal agent and therefore is ...
Niehaus D, Javorski M, Kay E, Rhoades A, Raidt H, Dowling R.   +5 more
europepmc   +2 more sources

Emergency reversal of Rivaroxaban with Andexanet alfa in a child with hemorrhagic brain metastasis from Wilms tumor. [PDF]

Childs Nerv Syst
Rafaelian A, Won SY, Mueller L, Armbrust M, Weber KJ, Haas A, Reuter DA, Freiman TM, Gessler F, Spang C, Meyer-Bahlburg A, Hingst P, Classen CF, Dubinski D, Cardesa-Salzmann TM.   +14 more
europepmc   +1 more source

Andexanet alfa Reduces Hematoma Expansion Following Controlled Cortical Impact in Mice Pretreated with Rivaroxaban. [PDF]

Neurocrit Care
Lieschke F, Gelhard S, Rosenthal-Rueckeis M, Grefkes C, Bohmann FO.   +4 more
europepmc   +1 more source

TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short. [PDF]

Blood Adv
Crossette-Thambiah C, Bamberg K, Laffan M, Ahnström J.   +3 more
europepmc   +1 more source

Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment: Postmarketing Surveillance Study in Japan. [PDF]

JACC Asia
Sakamoto K, Ishihara M, Kato H, Kim H, Okuda M, Hiroki S, Koga M, Toyoda K.   +7 more
europepmc   +1 more source

Comparing Hemostatic Efficacy of Four-factor Prothrombin Complex Concentrate with Andexanet Alfa in an Apixaban-treated Polytrauma Male Porcine Model. [PDF]

Anesthesiology
Grottke O, Braunschweig T, Heubner L, Herzog E, Rayatdoost F.   +4 more
europepmc   +1 more source

Successful use of an antithrombin for heparin resistance with andexanet alfa. [PDF]

JA Clin Rep, 2023
Honda J, Itakura Y, Tanaka S, Inoue S.
europepmc   +1 more source

Real-world clinical decision of andexanet alfa administration for intracranial hemorrhage during anticoagulant therapy using factor Xa inhibitor. [PDF]

J Crit Care Med (Targu Mures)
Yamashiro S, Harada K, Izumi S, Morikawa Y, Ikemoto T, Kameno K, Goto T, Ohmori Y, Kaji M, Mukasa A.   +9 more
europepmc   +1 more source